This informal CPD article ‘After the Fail: How Media Fill Responses Can Make or Break Inspections’, was provided by Pharmalliance Consulting, who offer specialist support to pharmaceutical companies to maintain and increase quality compliance level.
No one wants to fail a media fill, but it happens. What matters most is how you respond. In the past year, multiple inspections have shown that poor investigations and delayed actions after Aseptic Process Simulation (APS) failures can cause more regulatory trouble than the failure itself.
Where Things Go Wrong
Here’s what regulators are flagging:
- Investigations that stop at “Operator Error” without evidence.
- Repeating media fills without changing anything.
- Delayed recalls or production continuation after a failed APS.
In one case, the FDA found that a manufacturer had multiple failed aseptic process simulations (APS) but failed to perform a comprehensive investigation or implement effective corrective actions. Instead, the firm dismissed each failure as an isolated incident without conducting a thorough root-cause analysis. The FDA deemed this approach unacceptable and required the company to reassess its entire aseptic processing program to ensure the reliability of its operations.
Speed Matters
In another instance, a company experienced contamination during a media fill but failed to conduct an adequate investigation or implement timely corrective actions. The FDA emphasised that any contaminated unit in a media fill should be considered objectionable and thoroughly investigated to determine potential causes and assess the impact on product sterility. The lack of prompt response and comprehensive evaluation was viewed as a serious lapse in quality oversight and a risk to patient safety.
What a Strong Response Looks Like
When media fill failures are investigated properly, the outcomes can lead to meaningful improvements. Some of the strongest responses regulators have noted include:
- Using microbial ID and sequencing to track contamination sources.
- Reviewing historical EM data and APS records for trends.
- Enhancing training and oversight during critical interventions.
- Revalidating the line with at least three successful media fills.
Regulators appreciate when companies show they’ve learned something and applied those lessons across systems.
Communicating Risk Internally
One of the weaknesses inspectors often find is poor internal communication about media fill failures. Operators, maintenance teams, and support staff are sometimes unaware of the issue until long after it happens. In stronger programs, the investigation process includes open discussion across functions so that everyone involved in the process understands what went wrong and how their role connects to the outcome. This helps reinforce accountability and supports better prevention next time.
Documentation that Tells the Full Story
Strong media fill investigations include not only data but also clear reasoning. Inspectors often call out investigations that jump from symptom to conclusion without walking through the logic. A well-documented response clearly shows the progression from detection to investigation, from root cause to corrective action. Facilities that do this well are also more likely to spot trends across multiple events, which can prevent repeat issues.
Making APS Failures a Trigger for Wider Review
A growing expectation is that an APS failure triggers more than just a review of that one simulation. Some firms now use these failures as a prompt to reassess related procedures, operator qualifications, equipment maintenance logs, and even their contamination control strategy. Inspectors have noted that this type of broader review shows a mature quality culture, one that takes problems seriously and uses them to drive systemic improvement.
Conclusion
Media fill failures don’t have to mean disaster. But if they’re mishandled, they can call your entire aseptic process into question. Respond quickly, investigate deeply, and show your work.
We hope this article was helpful. For more information from Pharmalliance Consulting, please visit their CPD Member Directory page. Alternatively, you can go to CPD Industry Hubs for more articles, courses and events relevant to your Continuing Professional Development requirements.
References
U.S. Food and Drug Administration, 2023. Warning Letters Database, United States of America.
The European Commission, 2022. EU Annex 1, Brussels, Belgium.
